{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:28:22Z","timestamp":1713572902014},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,18]]},"DOI":"10.7759\/cureus.58570","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T06:10:35Z","timestamp":1713507035000},"source":"Crossref","is-referenced-by-count":0,"title":["Sezary Syndrome: A Case Report and Review of Current Therapeutics"],"prefix":"10.7759","author":[{"given":"Jayasree","family":"Krishnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kannan","family":"Thanikachalam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.3236","article-title":"Incidence trends of primary cutaneous T-cell lymphoma in the US from 2000 to 2018: a SEER population data analysis","volume":"8","author":"Cai ZR","year":"2022","unstructured":"Cai ZR, Chen ML, Weinstock MA, Kim YH, Novoa RA, Linos E. Incidence trends of primary cutaneous T-cell lymphoma in the US from 2000 to 2018: a SEER population data analysis. JAMA Oncol. 2022, 8:1690-2. 10.1001\/jamaoncol.2022.3236","journal-title":"JAMA Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1141108","article-title":"Mycosis fungoides and S\u00e9zary syndrome: clinical presentation, diagnosis, staging, and therapeutic management","volume":"13","author":"Miyashiro D","year":"2023","unstructured":"Miyashiro D, Sanches JA. Mycosis fungoides and S\u00e9zary syndrome: clinical presentation, diagnosis, staging, and therapeutic management. Front Oncol. 2023, 13:1141108. 10.3389\/fonc.2023.1141108","journal-title":"Front Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar NS","year":"2010","unstructured":"Agar NS, Wedgeworth E, Crichton S, et al.. Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010, 28:4730-9. 10.1200\/JCO.2009.27.7665","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002","volume":"143","author":"Criscione VD","year":"2007","unstructured":"Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol. 2007, 143:854-9. 10.1001\/archderm.143.7.854","journal-title":"Arch Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.036","article-title":"Early clinical manifestations of S\u00e9zary syndrome: a multicenter retrospective cohort study","volume":"77","author":"Mangold AR","year":"2017","unstructured":"Mangold AR, Thompson AK, Davis MD, et al.. Early clinical manifestations of S\u00e9zary syndrome: a multicenter retrospective cohort study. J Am Acad Dermatol. 2017, 77:719-27. 10.1016\/j.jaad.2017.05.036","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/hupa.2003.4","article-title":"Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells","volume":"34","author":"Magro CM","year":"2003","unstructured":"Magro CM, Crowson AN, Kovatich AJ, Burns F. Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells. Hum Pathol. 2003, 34:119-29. 10.1053\/hupa.2003.4","journal-title":"Hum Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.118538","article-title":"Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas","volume":"46","author":"Vonderheid EC","year":"2002","unstructured":"Vonderheid EC, Bernengo MG, Burg G, et al.. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002, 46:95-106. 10.1067\/mjd.2002.118538","journal-title":"J Am Acad Dermatol"},{"key":"ref8","unstructured":"Atlas of Haematological Cytology. (2016). Accessed. April 14, 2024: http:\/\/www.leukemia-cell.org\/atlas."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen E","year":"2007","unstructured":"Olsen E, Vonderheid E, Pimpinelli N, et al.. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007, 110:1713-22. 10.1182\/blood-2007-03-055749","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26760","article-title":"Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Hristov AC","year":"2023","unstructured":"Hristov AC, Tejasvi T, Wilcox RA. Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023, 98:193-209. 10.1002\/ajh.26760","journal-title":"Am J Hematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - update 2023","volume":"195","author":"Latzka J","year":"2023","unstructured":"Latzka J, Assaf C, Bagot M, et al.. EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - update 2023. Eur J Cancer. 2023, 195:113343. 10.1016\/j.ejca.2023.113343","journal-title":"Eur J Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"5","author":"Prince HM","year":"2017","unstructured":"Prince HM, Kim YH, Horwitz SM, et al.. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017, 5:555-66. 10.1016\/S0140-6736(17)31266-7","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"9","author":"Kim YH","year":"2018","unstructured":"Kim YH, Bagot M, Pinter-Brown L, et al.. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018, 9:1192-204. 10.1016\/S1470-2045(18)30379-6","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust MS","year":"2020","unstructured":"Khodadoust MS, Rook AH, Porcu P, et al.. Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study. J Clin Oncol. 2020, 38:20-8. 10.1200\/JCO.19.01056","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/168419-sezary-syndrome-a-case-report-and-review-of-current-therapeutics","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T06:10:39Z","timestamp":1713507039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/168419-sezary-syndrome-a-case-report-and-review-of-current-therapeutics"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.58570","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,18]]}}}